CoChat

Pyrazolo[1,5-a]pyrimidine as a Prominent Framework for Tropomyosin Receptor Kinase (Trk) Inhibitors—Synthetic Strategies and SAR Insights

Open access

The DOI matches its Crossref record; 79 of the 81 references it cites were found in a registry or an index.

Abstract

Tropomyosin receptor kinases (Trks) are transmembrane receptor tyrosine kinases named TrkA, TrkB, and TrkC and encoded by the NTRK1, NTRK2, and NTRK3 genes, respectively. These kinases have attracted significant attention and represent a promising therapeutic target for solid tumor treatment due to their vital role in cellular signaling pathways. First-generation TRK inhibitors, i.e., Larotrectinib sulfate and Entrectinib, received clinical approval in 2018 and 2019, respectively. However, the use of these inhibitors was significantly limited because of the development of resistance due to mutations. Fortunately, the second-generation Trk inhibitor Repotrectinib (TPX-0005) was approved by the FDA in November 2023, while Selitrectinib (Loxo-195) has provided an effective solution to this issue. Another macrocycle-based analog, along with many other TRK inhibitors, is currently in clinical trials. Two of the three marketed drugs for NTRK fusion cancers feature a pyrazolo[1,5-a] pyrimidine nucleus, prompting medicinal chemists to develop numerous novel pyrazolopyrimidine-based molecules to enhance clinical applications. This article focuses on a comprehensive review of chronological synthetic developments and the structure–activity relationships (SAR) of pyrazolo[1,5-a]pyrimidine derivatives as Trk inhibitors. This article will also provide comprehensive knowledge and future directions to the researchers working in the field of medicinal chemistry by facilitating the structural modification of pyrazolo [1,5-a]pyrimidine derivatives to synthesize more effective novel chemotherapeutics as TRK inhibitors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/molecules29153560

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Schematic presentation of Trk receptors and their major signal transduction pathway [53,54].
Figure 1 Schematic presentation of Trk receptors and their major signal transduction pathway [53,54].CC BY · PubMed Central
Figure 2 Development of NTRK fusion inhibitors consisting of a pyrazolo[1,5-a]pyrimidine moiety.
Figure 2 Development of NTRK fusion inhibitors consisting of a pyrazolo[1,5-a]pyrimidine moiety.CC BY · PubMed Central
Figure 3 Different fundamental isoforms of pyrazolopyrimidines.
Figure 3 Different fundamental isoforms of pyrazolopyrimidines.CC BY · PubMed Central
Figure 4 Schematic representation of various synthetic strategies to obtain the PP skeleton.
Figure 4 Schematic representation of various synthetic strategies to obtain the PP skeleton.CC BY · PubMed Central
Figure 5 SAR study of pyrrolidine-linked PP derivatives as TrkA inhibitors.
Figure 5 SAR study of pyrrolidine-linked PP derivatives as TrkA inhibitors.CC BY · PubMed Central
Figure 6 SAR study of carboxamide-linked PP derivatives as TrkA inhibitors.
Figure 6 SAR study of carboxamide-linked PP derivatives as TrkA inhibitors.CC BY · PubMed Central
Figure 7 SAR study of macrocyclic PP derivatives as Trk inhibitors.
Figure 7 SAR study of macrocyclic PP derivatives as Trk inhibitors.CC BY · PubMed Central
Figure 8 SAR study of heteroaryl-substituted PP derivatives as Trk inhibitors.
Figure 8 SAR study of heteroaryl-substituted PP derivatives as Trk inhibitors.CC BY · PubMed Central
Figure 9 SAR study of pyrazole- and triazole-substituted PP derivatives as TrkA WT inhibitors.
Figure 9 SAR study of pyrazole- and triazole-substituted PP derivatives as TrkA WT inhibitors.CC BY · PubMed Central
Figure 10 SAR study of nitrile-substituted PP derivatives as NTRK inhibitors.
Figure 10 SAR study of nitrile-substituted PP derivatives as NTRK inhibitors.CC BY · PubMed Central
Figure 11 SAR study of macrocyclic PP derivatives as NTRK inhibitors.
Figure 11 SAR study of macrocyclic PP derivatives as NTRK inhibitors.CC BY · PubMed Central
Figure 12 SAR study of 5-azabicyclohexane-substituted PP derivatives as Trk inhibitors.
Figure 12 SAR study of 5-azabicyclohexane-substituted PP derivatives as Trk inhibitors.CC BY · PubMed Central
Figure 13 SAR study of macrocyclic kinase inhibitors based on the PP scaffold.
Figure 13 SAR study of macrocyclic kinase inhibitors based on the PP scaffold.CC BY · PubMed Central
Figure 14 SAR study of amino PP derivatives as Trk inhibitors.
Figure 14 SAR study of amino PP derivatives as Trk inhibitors.CC BY · PubMed Central
Figure 15 SAR study of substituted PP macrocyclic derivatives as Trk inhibitors.
Figure 15 SAR study of substituted PP macrocyclic derivatives as Trk inhibitors.CC BY · PubMed Central
Figure 16 SAR study of macrocyclic PP derivatives as selective Trk inhibitors.
Figure 16 SAR study of macrocyclic PP derivatives as selective Trk inhibitors.CC BY · PubMed Central
Figure 17 SAR study of sulfonamide-substituted macrocyclic PP derivatives as Trk inhibitors.
Figure 17 SAR study of sulfonamide-substituted macrocyclic PP derivatives as Trk inhibitors.CC BY · PubMed Central
Figure 18 SAR study of novel PP-based TrkA, TrkB, and TrkC inhibitors.
Figure 18 SAR study of novel PP-based TrkA, TrkB, and TrkC inhibitors.CC BY · PubMed Central
Figure 19 SAR study of second-generation macrocyclic PP derivatives as Pan-Trk inhibitors.
Figure 19 SAR study of second-generation macrocyclic PP derivatives as Pan-Trk inhibitors.CC BY · PubMed Central
Figure 20 SAR study of 3-Pyrazolyl-substituted PP derivatives as Trk inhibitors.
Figure 20 SAR study of 3-Pyrazolyl-substituted PP derivatives as Trk inhibitors.CC BY · PubMed Central
Figure 21 SAR study of second-generation PP derivatives as Trk inhibitors.
Figure 21 SAR study of second-generation PP derivatives as Trk inhibitors.CC BY · PubMed Central
Figure 22 SAR study of 7-aryl-3-substituted PP derivatives as RTK and STK inhibitors.
Figure 22 SAR study of 7-aryl-3-substituted PP derivatives as RTK and STK inhibitors.CC BY · PubMed Central
Figure 23 SAR study of fused PP derivatives as TrkA inhibitors.
Figure 23 SAR study of fused PP derivatives as TrkA inhibitors.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 79 references

Research works printed but not linked: 4

  1. Kakizawa S. Neurotrophin-3 Handbook of Hormones (Second Edition) Ando H. Ukena K. Nagata S. Academic Press San Diego, CA, USA 2021 483 485 978-0-12-820649-2
  2. Batool Z. Azfal A. Liaquat L. Sadir S. Nisar R. Inamullah A. Faiz Ghalib A.U. Haider S. Receptor Tyrosine Kinases (RTKs): From Biology to Pathophysiology Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders Mansour H.M. Khattab M.M. El-khatib A.S. Academic Press Cambridge, MA, USA 2023 117 185 978-0-443-18677-6
  3. Numakawa T. Odaka H. Chapter 3—Roles of Trk Receptors, Tyrosine Kinase Receptors for Neurotrophins, in the Developing CNS Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders Mansour H.M. Khattab M.M. El-khatib A.S. Academic Press Cambridge, MA, USA 2023 79 115 978-0-443-18677-6
  4. Rashad A.E. Abdelmegid M. Shamroukh A.H. Abdelmegeid F.M. The Chemistry of Pyrazolopyrimidines and Their Applications Org. Chem. Ind. J. 2014 10 224 250

Cited by

See all 12

Metadata

Authors
Mahajan, A. T., Shivani, Datusalia, A. K., Coluccini, C., Coghi, P., & Chaudhary, S.
Affiliations
  • National Institute of Pharmaceutical Education and Research (IN)
  • China Medical University (TW)
  • Macau University of Science and Technology (MO)
Corresponding author
  • Coluccini, Carmine
  • Coghi, Paolo
  • Chaudhary, Sandeep
Venue
Molecules
Publisher
MDPI AG
Published
2024-07-29
Volume
29
Issue
15
Pages
3560
ISSN
1420-3049 (ISSN-L)
OpenAlex
W4401080166
Cited by
12
References
81
Citations by year
2026: 5 · 2025: 6 · 2024: 1
FWCI
0.49
Type
journal article
Language
en
Open access
Locations
  • Molecules (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • NIPER-Raebareli (CRG/2019/005102, MOST 110-2113-M-039-001, MOST 111-2221-E-039-009, 0005-2023-RIA1)
  • Science and Engineering Research Board (SERB) (CRG/2019/005102, MOST 110-2113-M-039-001, MOST 111-2221-E-039-009, 0005-2023-RIA1)
  • Ministry of Science and Technology in Taiwan (CRG/2019/005102, MOST 110-2113-M-039-001, MOST 111-2221-E-039-009, 0005-2023-RIA1)
  • Macao Science and Technology University (CRG/2019/005102, MOST 110-2113-M-039-001, MOST 111-2221-E-039-009, 0005-2023-RIA1)
Topics
  • Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
  • Physical Sciences › Chemistry › Organic Chemistry › Synthesis and Characterization of Heterocyclic Compounds
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
Keywords
Trk receptors, TRK inhibitors, pyrazolo[1,5-a]pyrimidines, structure-activity relationship, larotrectinib, entrectinib, repotrectinib, resistance mutations, synthetic strategies, tyrosine kinase inhibitors
MeSH terms
Antineoplastic Agents, Humans, Neoplasms, Pyrazoles, Pyrimidines, Structure-Activity Relationship, Receptor, trkC, Receptor, trkB, Receptor, trkA, Protein Kinase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.